Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
Section

Federal Policy

6 stories on Friday, November 20 · Page 1 of 44
Federal Policy

KFF Survey Finds Widespread Medicaid Home Care Workforce Shortages in 2026

In an issue brief, KFF reports on 2026 Medicaid payment rates for home care and workforce supports, drawing on its 24th survey of state officials who administer Medicaid home care programs, completed by nearly all states between April and August 2026. All responding states reported worker shortages, most often among nursing staff, direct support professionals, and personal care attendants, and 43 states reported permanent provider closures in the past year. Fewer states reported raising provider payment rates compared with 2025, even though increasing rates remains the most common strategy states use. The brief also compares KFF's statewide average payment data with the more detailed, but harder to compare, payment data states must now report under the Medicaid access rule, and notes that of 29 states reporting time-based personal care rates, more than half pay below $20 per hour.

Why it mattersState Medicaid agencies and home care providers may face continued workforce shortages and provider closures even as federal access rule reporting requirements could limit states' ability to cut payment rates amid pressure to reduce Medicaid spending.
KFF Research · 1 day ago

Latest

  1. Federal Policy

    CMS Finalizes CY 2027 Home Health Payment Rule, Raises Rates 2.4%

    CMS released its annual Home Health Prospective Payment System Final Rule for Calendar Year 2027 on November 4, 2026. CMS estimates Medicare payments to home health agencies will increase by 2.4 percent, or approximately $415 million, in CY 2027. The Final Rule also continues a 3.0 percent cut to the base payment rate, which CMS is using to recover what it views as past overpayments.

    jdsupra.com · 1 day ago
  2. Federal Policy

    Senate Judiciary Members Admit Drug Pricing Bills Remain Stalled

    At a Senate Judiciary Committee hearing, lawmakers including Sen. John Kennedy (R-La.) acknowledged that Congress has failed to advance drug pricing reform despite Republican control, with Kennedy calling the inaction "zero, zilch, nada." Chairman Chuck Grassley (R-Iowa) noted the committee advanced six bipartisan bills last year targeting drugmaker and PBM practices, but only one, the Affordable Prescriptions for Patients Act, reached the Senate floor; Grassley cited a crowded calendar and industry pushback as likely factors. Witnesses, including Patients for Affordable Drugs Now CEO Merith Basey and Cost Plus Drug Company CEO Alex Oshmyansky, testified that the bills should pass as a package to address patent abuses like product hopping and patent thickets, and that PBM consolidation among CVS Caremark, Express Scripts and OptumRx drives high costs and limits competition.

    Healthcare Dive · 2 days ago
  3. Federal Policy

    Congressional Commission Warns US Pharma Depends on China Biotech

    The National Security Commission on Emerging Biotechnology, a congressional body, warned in a Nov. 18 brief that China is working to control the pharmaceutical supply chain from manufacturing to drug discovery, and that U.S. drugmakers' growing licensing deals with Chinese biotechs are deepening American dependence. The commission said China published a pharmaceutical-focused follow-on to its 15th Five-Year Plan in September setting 2030 goals for more first-in-class drugs and global sales, and analyzed 57 deals between the 15 largest U.S. drugmakers and 42 Chinese biotechs from January 2023 to October 2026, finding rising up-front payments and escalating deal structures. It pointed to China's October proposal, not yet final, to restrict exports of certain next-generation biopharmaceutical technologies. The brief noted the FDA this month rejected a Chinese-invented lung cancer drug, and that generic drugs rely primarily on India and China for active ingredients while the U.S. accounts for only 12% of production.

    Becker's · 2 days ago
  4. Federal Policy

    OIG Flags 10 Drug Codes for Medicare Part B Price Substitution

    OIG compared Medicare Part B average sales prices (ASPs) with average manufacturer prices (AMPs) for the second quarter of 2026, as required under the Social Security Act. OIG found that 10 drug codes exceeded the AMP by more than 5 percent for two consecutive quarters or three of the previous four quarters, meeting CMS's criteria for price substitution. OIG is sending these 10 drug codes to CMS for review to determine whether to substitute lower payment rates to limit excessive Part B drug payments.

    oig.hhs.gov · 2 days ago
  5. Federal Policy

    ASPR Maps US Medical Plants to Spot Supply Chain Risks

    The Administration for Strategic Preparedness and Response, an HHS agency, is working with manufacturers and government partners to identify healthcare supply-chain vulnerabilities, according to a Nov. 18 news release. ASPR's Center for Industrial Base Management and Supply Chain is examining dependencies across the medical production chain and mapping manufacturing plants nationwide to find where added domestic capacity could reduce reliance on a single source or vulnerable foreign supplier. The mapping can support earlier coordination with manufacturers and federal partners ahead of events like a forecast hurricane. ASPR has also built resilience measures into federal manufacturing contracts and established the Biopharmaceutical Manufacturing Preparedness Consortium to expand manufacturing capacity and strengthen access to critical supplies.

    Becker's · 2 days ago
  6. Federal Policy

    Surgeons Say CMS 2027 Fee Rule Penalizes Efficiency, Same-Day Care

    CMS finalized the 2027 Medicare physician fee schedule on Nov. 4, cutting the conversion factor 2.31% to $32.63 for physicians not in a qualifying advanced alternative payment model, a deeper cut than the 1.68% CMS had proposed. The rule keeps a 2.5% "efficiency adjustment" begun in 2026 that reduced work RVUs and intraservice time for about 7,700 codes, and it cuts work RVUs for total hip and knee replacement 12.6%. It also finalizes a 20% payment reduction, down from a proposed 50%, for same-day evaluation and management visits billed with modifier 25 alongside 0-day global procedures. Surgeons Charles Taunt and Thomas Tsai told Becker's the changes undervalue team-based work that supports shorter procedures and same-day care, and the American College of Surgeons cited a study showing operative times rose 3.1% from 2019 to 2023.

    Becker's · 3 days ago
  7. Federal Policy

    ONDCP Credits Trump for Overdose Drop Researchers Trace to Biden Era

    NPR reports that the White House and ONDCP Director Sara Carter credited Trump administration border security and anti-cartel efforts for a roughly 41.5% decline in overdose deaths from their peak, saying gains occurred primarily over the last 18 months. CDC data cited by NPR shows the decline actually began in 2023 under the Biden administration and has continued for at least 39 consecutive months, with roughly one-third of the drop occurring before Trump returned to office. Drug policy researchers Vanda Felbab-Brown of Brookings and Nabarun Dasgupta of UNC Chapel Hill credit Biden-era policies, including expanded naloxone access, healthcare access, and a deal with China curbing fentanyl precursor chemicals, for much of the progress, while noting declines have continued under Trump. Carter responded that Biden "doesn't get to take credit" for reductions following what she called his own failure to secure the border.

    NPR · 3 days ago
  8. Federal Policy

    The Hill to Host Briefing on Alzheimer's Blood Test Screening Bill

    The Hill, in partnership with HealthyWomen, is hosting a live policy briefing on the Alzheimer's Screening and Prevention Act (ASAP), bipartisan legislation that would allow Medicare to cover FDA-approved blood tests for Alzheimer's screening, which Medicare currently is not authorized to cover. The event features lawmakers, health experts, patients and advocates, and cites a HealthyWomen survey finding only 13 percent of women ages 45-64 are aware such blood tests exist, despite 90 percent expressing interest in taking one. The event also features This is ALZ, a HealthyWomen campaign highlighting experiences of people living with early-stage Alzheimer's. The briefing is scheduled to begin at 12:30 p.m. EST.

    The Hill · 3 days ago
  9. Federal Policy

    FDA Proposes Withdrawing Liquid Statin FloLipid Over Missed Reports

    The FDA proposed withdrawing approval of FloLipid, a liquid formulation of simvastatin, after manufacturer Salerno Pharmaceuticals failed to file required annual reports, according to a Nov. 18 notice in the Federal Register. These annual reports convey labeling updates and manufacturing and controls information, per FDA policy. The agency is offering Salerno Pharma the chance to request a hearing to argue against the withdrawal. FloLipid was approved in April 2016 and marketed as the first liquid statin available in the U.S. for patients who have trouble swallowing pills; generic simvastatin tablets remain widely available.

    Becker's · 3 days ago
  10. Federal Policy

    Sanders to Outline Senate Democrats' Healthcare Priorities

    Sen. Bernie Sanders (I-Vt.) was set to outline Senate Democrats' healthcare priorities Wednesday morning, weeks after Democrats secured control of both chambers of Congress for next year. Sanders, who is poised to chair the Senate Health, Education, Labor and Pensions Committee, was also expected to renew his push for Medicare for All. The remarks follow Democrats' midterm focus on rising healthcare costs after enhanced Affordable Care Act subsidies expired last year, and come after the Trump administration withdrew its FDA commissioner nominee amid bipartisan opposition. The press conference was scheduled for 11 a.m. EST.

    The Hill · 3 days ago
  11. Federal Policy

    WEDI Survey Finds Most Payers Unready for Prior Authorization API Deadline

    A new Workgroup for Electronic Data Interchange survey finds only 1 in 10 payers are fully ready to implement electronic prior authorization APIs required under CMS's 2024 Interoperability and Prior Authorization Final Rule. The rule applies to Medicare, Medicaid managed care, CHIP and some federal exchange plans, requiring faster decisions, detailed denial reasons, public reporting, and by January 1 a set of APIs enabling automated data sharing and prior authorization workflows. Nearly two-thirds of plans are at least halfway done, but 17% haven't started, and payers cite difficulty connecting disparate systems and adapting workflows. Most payers (62%) report compliance costs exceeding expectations, and CMS estimates first-year industry costs of $182 million, rising to $1.6 billion over a decade; providers, though not required to build APIs, are also largely unprepared.

    Healthcare Dive · 3 days ago
  12. Federal Policy

    GAO Finds CMS Fraud Risk Process Misses Key Medicare Risks

    GAO reports that CMS's Center for Program Integrity uses a Vulnerability Management Process to manage fraud risks in traditional Medicare, which covered nearly $481 billion in benefits for about 34 million beneficiaries in 2025. GAO found this process is too broad and does not fully identify or assess fraud risks consistent with leading practices, missing risks that GAO identified through review of HHS Inspector General reports. The process also does not assess the likelihood and impact of identified risks or evaluate whether existing controls are adequate, citing the supplier enrollment screening process as an example where CPI identified a vulnerability but did not assess it as a fraud risk. GAO compared CMS practices against its own Fraud Risk Framework and internal control requirements.

    GAO · 3 days ago
  13. Federal Policy

    Sanders Plans Medicare for All Push as Likely HELP Chair

    Sen. Bernie Sanders (I-Vt.) told the Associated Press he will push a four-year Medicare for All plan atop the Democratic agenda when he is expected to chair the Senate HELP Committee next year. The plan would lower the Medicare eligibility age to 55 in year one, add dental and vision coverage, guarantee coverage for children through age 18, then drop the eligibility age to 45 in year two and 35 in year three before covering all Americans in year four. Sanders views budget reconciliation as a path around a Senate filibuster, though the source notes President Trump would likely veto it. Speaker Hakeem Jeffries has separately endorsed lowering the Medicare eligibility age, while Sen.-elect Chris Pappas (D-N.H.) said his top priority is stopping an estimated $1 trillion in Medicaid cuts, and the House Budget Committee estimates Medicare for All would cost $32 trillion over 10 years.

    The Hill · 3 days ago
  14. Federal Policy

    FDA Grants Accelerated Approval to Nuvalent's ALK Lung Cancer Drug

    The FDA granted accelerated approval on Nov. 17 to Nuvalent's Nelkarmi (neladalkib) for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer. The drug is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy. Approval was based on the phase 1/2 ALKOVE-1 trial, where response rates were 49% among alectinib-pretreated patients and 32% among those with prior multiple ALK inhibitors and chemotherapy. The prescribing information warns of liver, kidney and eye toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity; the recommended dose is 150 mg orally once daily. The application received priority review, breakthrough therapy, and orphan drug designations.

    Becker's · 3 days ago
  15. Federal Policy

    NIH Names NIAID Chief as Trump's GAO, FDA Picks Advance

    Becker's Hospital Review reports on three federal healthcare leadership changes. The NIH named John Powers III, MD, permanent director of its National Institute of Allergy and Infectious Diseases after he led the institute on an acting basis since June, with NIH Director Jay Bhattacharya citing his focus on rigor and research outcomes. President Trump sent the Senate a nomination for Eric Ueland to serve as comptroller general, a 15-year term heading the Government Accountability Office, which audits HHS, CMS and the FDA and appoints members to MedPAC and MACPAC, the commissions that advise Congress on Medicare and Medicaid payment rates. Separately, the Senate HELP Committee will vote Nov. 18 on Trump's FDA commissioner nominee, Heidi Overton, MD, PhD, amid a physician coalition letter urging rejection and Washington Post reporting that some administration officials have discussed abandoning her nomination.

    Becker's · 3 days ago
  16. Federal Policy

    CMS Sets 2027 Medicare Part A and B Premiums, Deductibles

    CMS announced the 2027 Medicare Part A and Part B premiums, deductibles, and coinsurance amounts, along with Part D income-related monthly adjustment amounts. The standard Part B monthly premium rises to $209.40, up $6.50 from 2026, and the Part B annual deductible increases to $292, up $9. The Part A inpatient hospital deductible rises to $1,776, with corresponding increases in hospital and skilled nursing facility coinsurance and in Part A buy-in premiums for those without 40 quarters of coverage. CMS states the Part B increase is mainly due to projected increases in healthcare spending; the changes take effect in 2027.

    CMS · 3 days ago
  17. Federal Policy

    SAMHSA, NASADAD Launch Policy Academy on Opioid Abatement Funds

    SAMHSA, working with the National Association of State Alcohol and Drug Agency Directors, kicked off a state policy academy to help state teams plan how to use opioid abatement funding. The academy is designed to help states strategically leverage these funds to strengthen substance use prevention, treatment, and recovery support services. The funds are designated to address the effects of opioid addiction and overdose and can be coordinated with other funding sources.

    SAMHSA · 3 days ago
  18. Federal Policy

    CMS Reports Medicare Improper Payments Rose to $33.96B in FY2026

    CMS reported Medicare fee-for-service improper payments reached an estimated $33.96 billion in FY2026, up 0.77% from $28.83 billion in FY2025, representing 7.32% of original Medicare claims. CMS said improper payments do not necessarily indicate fraud but acknowledged some portion may involve fraud, waste or abuse, and it expects future rates to be affected by fraudulent claims in hospice and home health reimbursement specifically. The data covered claims submitted from July 1, 2024 through June 30, 2025, predating CMS's proposed CRUSH rule, its home health and hospice enrollment moratoria, and its new ClaimsCore platform. CMS said it expects FY2027 improper payment data to reflect these newer program integrity efforts, including AI data analytics and coordination with HHS OIG.

    hospicenews.com · 3 days ago
  19. Federal Policy

    CMS Extends Home Health Moratorium, Lets Existing Providers Add Locations

    CMS extended its nationwide Medicare home health and hospice enrollment moratorium by six months, modifying the policy to let currently enrolled providers add new practice locations under existing Medicare enrollments, while continuing to block new initial enrollments and certain majority-ownership changes. Providers and attorneys quoted by Home Health Care News say the change favors established operators, who can now expand through new branches or acquisitions of other enrolled providers, over new market entrants. Industry sources including New Day Healthcare and Bayada Home Health Care support CMS's anti-fraud goals but warn the broad restrictions could reduce competition and limit access in rural and underserved areas. CMS has said it has not seen evidence the original moratorium materially reduced beneficiaries' access to care nationwide or at the state level.

    Home Health Care News · 3 days ago
  20. Federal Policy

    CMS Unveils Roadmap for AI Adoption Across Health Care Payment, Regulation

    CMS released a roadmap on November 13, 2026 outlining the administration's approach to what it calls "clinical super intelligence" (CMS's term for AI) in health care, describing phased implementation prioritizing low-risk applications. The roadmap envisions new outcome-based payment models for chronic care, preventive care, and SI-led accountable care, building on existing CMS models, and suggests portions of Medicare annual wellness visits could be delivered via AI. CMS also aims to replace state-by-state AI regulation with a national standard, partner with FDA on streamlined approval pathways for AI-enabled medical devices, and expand data access for patients, providers, payors, and developers. The document is described as aspirational and non-binding, with no mandated adoption timeline given.

    jdsupra.com · 3 days ago

Get the daily briefing.